BiologicalDrug
JX-594 clinical trials
Also written JX-594.
- studies test it
- 15
- open now
- 0
- in phase 3
- 1
- first study started
- 2007
How studies write it
Studies that test it under each name
Name
Other names
Combined with it in one product
Studies by the year they started
15 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 9
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 4
Jennerex Biotherapeutics (8) · SillaJen, Inc. (2) · Centre Leon Berard (1) · Samsung Medical Center (1) · Transgene (1) · Institut Bergonié (1) · Andrea McCart (1)
Often tested with
Tested in the same studies.
Sorafenib (1) · Cemiplimab (1) · Ipilimumab (1) · Nivolumab (1) · Cyclophosphamide (1) · Avelumab (1)
Studies
Open first, then newest update. How each study uses JX-594 is read from its arms, and is right about nine times in ten.
Testing it · 15
- Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver ResectionTerminatedPhase 2Jennerex BiotherapeuticsNCT01329809Written as Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- A Study of Recombinant Vaccinia Virus to Treat Malignant MelanomaCompletedPhase 1/2Jennerex BiotherapeuticsNCT00429312Written as JX-594
- A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular CarcinomaCompletedPhase 2Jennerex BiotherapeuticsNCT01171651Written as JX-594
- A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed SorafenibCompletedPhase 2Jennerex BiotherapeuticsNCT01387555Written as JX-594 recombinant vaccina GM-CSF
- Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal CarcinomaCompletedPhase 1Jennerex BiotherapeuticsNCT01380600Written as Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell CarcinomaCompletedPhase 1/2SillaJen, Inc.NCT03294083Written as Pexastimogene Devacirepvec (Pexa-Vec)
- Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib AloneCompletedPhase 3SillaJen, Inc.NCT02562755Written as Pexastimogene Devacirepvec (Pexa Vec)
- Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.CompletedPhase 1Centre Leon BerardNCT02977156Written as Pexa-Vec
- A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)Status unknownPhase 1/2Institut BergoniéNCT02630368Written as Cyclophosphamide and JX-594
- A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)TerminatedPhase 1/2TransgeneNCT03071094Written as Pexastimogene Devacirepvec (Pexa Vec)
- A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver CancerCompletedPhase 2Jennerex BiotherapeuticsNCT01636284Written as JX-594 recombinant vaccina GM-CSF
- A Trial of JX-594 in Refractory Colorectal CarcinomaCompletedPhase 1Samsung Medical CenterNCT01469611Written as JX-594
- Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric PatientsCompletedPhase 1Jennerex BiotherapeuticsNCT01169584Written as Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid TumorsCompletedPhase 1Jennerex BiotherapeuticsNCT00625456Written as Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer OriginWithdrawnPhase 2Andrea McCartNCT02017678Written as JX-594
Given in every arm · 2 — JX-594 is usual care beside what is tested
- Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal CarcinomaCompletedPhase 1/2Jennerex BiotherapeuticsNCT01394939Written as JX-594
- A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT03206073Written as Pexa-Vec